Clinical Research Studies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Multiple Sclerosis
• Age: Between 18 years - 45 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  All Participants:

  1. Subjects who are able to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations
  2. Male and Female subjects between 18 and 45 years
  3. Subjects with WRAT-4 Reading standard score of 85 to 115
  4. Subjects who are able to undergo neuroimaging data collection procedures

  For MS Participants:

  1. Subjects with definite diagnosis of RRMS
  2. Subjects who have adequate vision as reported by the participant
  3. Subjects who have EDSS of 0 to 6.0
  4. Subjects who are clinically prescribed Tecfidera, Tysabri or Ocrevus therapy by treating neurologist, with first dose being within 3 months + 14 days from baseline visit
  5. Subjects who are at baseline visit, concurrent medications to be kept constant over three months prior to data collection visits
  6. Subjects who have no relapse or steroids in previous month

  
  

You may not be eligible for this study if the following are true:

• All Participants:

  1. Subjects who are unable or unwilling to provide informed consent.
  2. Subjects with Beck Depression Inventory-Fast Screen (BDI-FS) score of 4 or more
  3. Subjects currently have alcohol or other substance use disorder
  4. Subjects with primary psychiatric disorder that would adversely influence ability to participate
  5. Subjects with other neurological condition associated with cognitive impairment
  6. Subjects with other serious uncontrolled medical condition
  7. Subjects with learned English language after 12 years of age
  8. Subjects who have low absolute low lymphocyte count (ALC), USPI guidance will be utilized
  9. For MS participants: Lemtrada, Cladribine, Mitoxantrone